{"id":"NCT01610687","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis","officialTitle":"A Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-07","primaryCompletion":"2005-02","completion":"2005-02","firstPosted":"2012-06-04","resultsPosted":"2012-08-17","lastUpdate":"2023-01-10"},"enrollment":137,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis","Spasticity"],"interventions":[{"type":"DRUG","name":"GW-1000-02","otherNames":["Sativex"]}],"arms":[{"label":"GW-1000-02","type":"EXPERIMENTAL"}],"summary":"An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.","primaryOutcome":{"measure":"Incidence of Adverse Events as a Measure of Patient Safety","timeFrame":"up to1206 days","effectByArm":[{"arm":"GW-1000-02","deltaMin":126,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":14},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":["17086911"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":137},"commonTop":["URINARY TRACT INFECTION NOS","NASOPHARYNGITIS","ORAL PAIN","DIZZINESS","DIARRHOEA NOS"]}}